Pancreatic Cancer Research

ResearcherNorthwestern UniversityActive in the last 2 years

Sheetal Mehta Kircher

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3429-6378; OpenAlex author ID A5090074262. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 4

  1. KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials. Co-author DOI 10.3390/cancers18132037↗
  2. Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC). Co-author DOI 10.1038/s41416-023-02344-5↗
  3. Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. Co-author DOI 10.1634/theoncologist.2019-0473↗
  4. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients. Co-author DOI 10.1586/era.11.125↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Al B. Benson · 4 shared papers, 2011–2026 · strength 0.60
  2. Mary F. Mulcahy · 4 shared papers, 2011–2026 · strength 0.60
  3. Aparna Kalyan · 3 shared papers, 2020–2026 · strength 0.57
  4. Devalingam Mahalingam · 2 shared papers, 2023–2026 · strength 0.45
  5. Tarık Demir · 1 shared paper, 2026 · strength 0.29
  6. Dılşa Mızrak Kaya · 1 shared paper, 2026 · strength 0.29
  7. Bin Zhang · 1 shared paper, 2023 · strength 0.16
  8. Halla Sayed Nimeiri · 2 shared papers, 2011–2020 · strength 0.16
  9. Suneel Deepak Kamath · 1 shared paper, 2020 · strength 0.13
  10. Seth B. Krantz · 1 shared paper, 2011 · strength 0.03
  11. Hidayatullah G. Munshi · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.